Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells

a Evolution of CLL cells count and (B) Ki67+ cells for the 16 patients included in the study comparing treatment-na？ve (TN) and relapsed-refractory (RR) patients during (a) the first 120 days or (b) up to 9 months on Ibrutinib. Peripheral CLL cell counts from peripheral blood are expressed as a ratio vs. cell count the day of the first Ibrutinib ingestion. Paired Student’s t-test has been performed comparing cell count at variable time points compared to T0, *t-value？<？0.05, **t-value？<？0.01 and ***t-value？<？0.001. Student’s t-test has also been performed comparing TN to RR for each time point, +t-value？<？0.0